These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33509226)

  • 1. The miR-1185-2-3p-GOLPH3L pathway promotes glucose metabolism in breast cancer by stabilizing p53-induced SERPINE1.
    Xu Y; Chen W; Liang J; Zeng X; Ji K; Zhou J; Liao S; Wu J; Xing K; He Z; Yang Y; Liu Q; Zhu P; Liu Y; Li L; Liu M; Chen W; Huang W
    J Exp Clin Cancer Res; 2021 Jan; 40(1):47. PubMed ID: 33509226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.
    He S; Niu G; Shang J; Deng Y; Wan Z; Zhang C; You Z; Shen H
    J Exp Clin Cancer Res; 2017 Oct; 36(1):137. PubMed ID: 28978336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MircoRNA-1275 promotes proliferation, invasion and migration of glioma cells via SERPINE1.
    Wu DM; Wang S; Wen X; Han XR; Wang YJ; Fan SH; Zhang ZF; Shan Q; Lu J; Zheng YL
    J Cell Mol Med; 2018 Oct; 22(10):4963-4974. PubMed ID: 30024092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
    Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
    Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-361-3p promotes human breast cancer cell viability by inhibiting the E2F1/P73 signalling pathway.
    Hua B; Li Y; Yang X; Niu X; Zhao Y; Zhu X
    Biomed Pharmacother; 2020 May; 125():109994. PubMed ID: 32092817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of miRNA-141 in breast cancer cells is associated with cell migration and invasion: involvement of ANP32E targeting.
    Li P; Xu T; Zhou X; Liao L; Pang G; Luo W; Han L; Zhang J; Luo X; Xie X; Zhu K
    Cancer Med; 2017 Mar; 6(3):662-672. PubMed ID: 28220627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma.
    Deng R; Huang JH; Wang Y; Zhou LH; Wang ZF; Hu BX; Chen YH; Yang D; Mai J; Li ZL; Zhang HL; Huang Y; Peng XD; Feng GK; Zhu XF; Tang J
    Mol Cancer; 2020 Aug; 19(1):122. PubMed ID: 32771023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamate metabotropic receptor 4 (GRM4) inhibits cell proliferation, migration and invasion in breast cancer and is regulated by miR-328-3p and miR-370-3p.
    Xiao B; Chen D; Zhou Q; Hang J; Zhang W; Kuang Z; Sun Z; Li L
    BMC Cancer; 2019 Sep; 19(1):891. PubMed ID: 31492116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA NEAT1 accelerates breast cancer progression through regulating miR-410-3p/ CCND1 axis.
    Liu X; Yao W; Xiong H; Li Q; Li Y
    Cancer Biomark; 2020; 29(2):277-290. PubMed ID: 32675392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.
    Xue J; Chi Y; Chen Y; Huang S; Ye X; Niu J; Wang W; Pfeffer LM; Shao ZM; Wu ZH; Wu J
    Oncogene; 2016 Jan; 35(4):448-58. PubMed ID: 25867061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway.
    Zhang M; Wang Y; Jiang L; Song X; Zheng A; Gao H; Wei M; Zhao L
    J Exp Clin Cancer Res; 2021 Jan; 40(1):41. PubMed ID: 33494806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway.
    Zheng A; Song X; Zhang L; Zhao L; Mao X; Wei M; Jin F
    J Exp Clin Cancer Res; 2019 Jul; 38(1):305. PubMed ID: 31300015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A miRNA-HERC4 pathway promotes breast tumorigenesis by inactivating tumor suppressor LATS1.
    Xu Y; Ji K; Wu M; Hao B; Yao KT; Xu Y
    Protein Cell; 2019 Aug; 10(8):595-605. PubMed ID: 30710319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long noncoding RNA MIR210HG promotes tumor metastasis by acting as a ceRNA of miR-1226-3p to regulate mucin-1c expression in invasive breast cancer.
    Li XY; Zhou LY; Luo H; Zhu Q; Zuo L; Liu GY; Feng C; Zhao JY; Zhang YY; Li X
    Aging (Albany NY); 2019 Aug; 11(15):5646-5665. PubMed ID: 31399552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-302a-5p/367-3p-HMGA2 axis regulates malignant processes during endometrial cancer development.
    Ma J; Li D; Kong FF; Yang D; Yang H; Ma XX
    J Exp Clin Cancer Res; 2018 Feb; 37(1):19. PubMed ID: 29391048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA SPRY4-IT1 regulates breast cancer cell stemness through competitively binding miR-6882-3p with TCF7L2.
    Song X; Zhang X; Wang X; Chen L; Jiang L; Zheng A; Zhang M; Zhao L; Wei M
    J Cell Mol Med; 2020 Jan; 24(1):772-784. PubMed ID: 31736268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-590-3P suppresses cell survival and triggers breast cancer cell apoptosis via targeting sirtuin-1 and deacetylation of p53.
    Abdolvahabi Z; Nourbakhsh M; Hosseinkhani S; Hesari Z; Alipour M; Jafarzadeh M; Ghorbanhosseini SS; Seiri P; Yousefi Z; Yarahmadi S; Golpour P
    J Cell Biochem; 2019 Jun; 120(6):9356-9368. PubMed ID: 30520099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway.
    Qiao K; Ning S; Wan L; Wu H; Wang Q; Zhang X; Xu S; Pang D
    J Exp Clin Cancer Res; 2019 Oct; 38(1):418. PubMed ID: 31623640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
    BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-410 Acts as a Tumor Suppressor in Estrogen Receptor-Positive Breast Cancer Cells by Directly Targeting ERLIN2 via the ERS Pathway.
    Wu H; Li J; Guo E; Luo S; Wang G
    Cell Physiol Biochem; 2018; 48(2):461-474. PubMed ID: 30016800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.